MDGL
Madrigal Pharmaceuticals, Inc.
$534.24
-25.77
(-4.60%)
Mkt Cap
12.40B
Volume
207,849
52W Range
286.44-615
Sector
Healthcare
Beta
-1.06
EPS (TTM)
-12.80
P/E Ratio
-45.32
Revenue (TTM)
1.13B
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 958.40M | 180.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (288.28M) | (465.89M) | (373.63M) | (295.35M) | (241.85M) | (202.24M) | (83.95M) | (32.81M) | (31.15M) | (26.39M) | (6.84M) | (86.16M) |
| EPS | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 |
| Free Cash Flow | (190.02M) | (457.03M) | (325.71M) | (225.07M) | (184.13M) | (157.90M) | (41.80M) | (25.53M) | (22.44M) | (17.61M) | (71.50M) | (79.07M) |
| FCF / Share | -8.47 | -21.48 | -17.43 | -13.13 | -11.14 | -10.22 | -2.71 | -1.73 | -1.83 | -3.38 | -418.11 | -28.10 |
| Operating CF | (189.55M) | (455.57M) | (324.23M) | (224.86M) | (183.92M) | (157.56M) | (41.62M) | (25.51M) | (22.32M) | (17.61M) | (71.44M) | (78.92M) |
| Total Assets | 1.26B | 1.04B | 640.55M | 362.57M | 273.33M | 287.00M | 442.06M | 485.43M | 192.31M | 41.21M | 68.19M | 100.67M |
| Total Debt | 354.36M | 119.57M | 117.19M | 49.89M | 797,000 | 786,000 | 676,000 | 0 | 0 | 0 | 4.65M | 13.91M |
| Cash & Equiv | 198.69M | 100.02M | 99.92M | 331.55M | 36.27M | 54.00M | 46.70M | 57.38M | 148.63M | 40.50M | 34.97M | 46.02M |
| Book Value | 602.69M | 754.38M | 405.33M | 197.39M | 196.11M | 239.97M | 416.56M | 476.98M | 182.26M | 36.41M | 50.41M | 65.14M |
| Return on Equity | -0.48 | -0.62 | -0.92 | -1.50 | -1.23 | -0.84 | -0.20 | -0.07 | -0.17 | -0.72 | -0.14 | -1.32 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 311.34M | 321.08M | 287.27M | 212.80M | 137.25M | 103.32M | 62.17M | 14.64M | 0 | 0 | 0 | 0 |
| Net Income | (94.39M) | (58.58M) | (114.19M) | (42.28M) | (73.24M) | (59.42M) | (106.96M) | (151.97M) | (147.54M) | (112.19M) | (98.74M) | (85.80M) |
| EPS | -3.25 | -2.57 | -5.08 | -1.90 | -3.32 | -2.71 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 | -4.69 |
| Free Cash Flow | (171.28M) | (133.07M) | 78.99M | (47.05M) | (88.89M) | (104.68M) | (67.76M) | (140.08M) | (149.51M) | (80.97M) | (85.26M) | (75.38M) |
| FCF / Share | -5.90 | -5.93 | 3.51 | -2.12 | -4.02 | -4.77 | -3.12 | -6.54 | -7.47 | -4.10 | -4.61 | -4.12 |
| Operating CF | (167.44M) | (133.46M) | 79.85M | (47.05M) | (88.89M) | (104.49M) | (66.98M) | (134.94M) | (149.16M) | (79.93M) | (84.92M) | (75.31M) |
| Total Assets | 1.23B | 1.26B | 1.36B | 1.02B | 996.63M | 1.04B | 1.07B | 1.10B | 1.08B | 640.55M | 237.96M | 302.46M |
| Total Debt | 347.31M | 354.36M | 346.40M | 123.95M | 119.77M | 119.57M | 119.14M | 118.06M | 117.72M | 117.19M | 116.56M | 99.66M |
| Cash & Equiv | 232.19M | 198.69M | 295.69M | 186.19M | 183.65M | 100.02M | 232.68M | 494.60M | 622.52M | 99.92M | 62.05M | 77.20M |
| Book Value | 543.45M | 602.69M | 625.73M | 695.98M | 710.64M | 754.38M | 777.15M | 857.12M | 850.76M | 405.33M | 22.25M | 103.51M |
| Return on Equity | -0.17 | -0.10 | -0.18 | -0.06 | -0.10 | -0.08 | -0.14 | -0.18 | -0.17 | -0.28 | -4.44 | -0.83 |
MDGL News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Madrigal Pharmaceuticals Could Become The Next Vertex